Please ensure Javascript is enabled for purposes of website accessibility

How Genomics Research Could Change How Multiple Sclerosis Is Treated

By Keith Speights and Jason Hall - Apr 5, 2021 at 7:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

10x Genomics CEO Serge Saxonov thinks we're at the threshold of some big discoveries.

Multiple sclerosis (MS) affects more than 1 million people in the U.S. But advances in treating the disease continue to be made, especially with new tools for genomic research into the underlying issues that lead to MS. In this video recorded on March 11, 2021, Jason Hall, multimedia specialist with The Motley Fool and the host of Discovery Now, talks with 10x Genomics (TXG 6.68%) CEO and co-founder Serge Saxonov about how genomics research could change how MS is treated.

Jason Hall: One of our members, Paolo, has submitted a question and I want to put a twist on it. Paolo's question is, "Do you view that we're early in the understanding of multiple sclerosis?"

But what I thought would be interesting is thinking about it from that same long-term mindset that you have that phenotype you said and talked about cancer the same way. But let's talk about it with something like MS. It's different in terms of what it is and infects us. Can you elaborate on that?

Serge Saxonov: Yeah. I think there's still quite a bit of unknowns about what causes it, but I think it is an example of a disease that we could be very much on the threshold of really figuring out what is going on. Because it is a disease of the immune system and we are now gaining a really great, fine view of what the immune system does and what is it that it is reacting to, something that only a few years ago we really had no means of doing.

I think we are actually probably on a path to understanding what is it about the immune system that gets dysregulated and again, moving from a place where it was very much a black box to understanding.

Then the next question is, how do we modulate the immune system or the agent that causes that overreaction in the immune system. I think once we understand, we're going to have quite a few tools to affect it as well. I think we're early, but we're not far away from potentially huge advances, I think, at the same time.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

10x Genomics, Inc. Stock Quote
10x Genomics, Inc.
TXG
$49.99 (6.68%) $3.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.